[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-thrombotic-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-thrombotic-syndrome":60},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,77,105,141,169],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100493189","defiance-rct-of-clottriever-system-versus-anticoagulation-in-deep-vein-thrombosis-100493189",false,"NCT05701917","DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis","DEFIANCE - ClotTriever® Thrombectomy System vs. Anticoagulation Alone for Treatment of Deep Vein Thrombosis","DEFIANCE","Inclusion Criteria\n\n* Age ≥ 18 years\n* Proximal lower extremity unilateral DVT involving at least the common femoral, external iliac, or common iliac veins, alone or in combination\n* Symptom onset within 12 weeks of enrollment in the study\n* Significant symptoms, as defined by a Villalta score \\> 9\n* Willing and able to provide informed consent\n\nExclusion Criteria\n\n* Bilateral iliofemoral DVT\n* Prior venous stent in the target venous segment\n* IVC aplasia\u002Fhypoplasia or other congenital anatomic anomalies of the IVC or iliac veins\n* IVC filter in place at the time of enrollment\n* Limb-threatening circulatory compromise (e.g., phlegmasia)\n* Clot in transit including IVC thrombus presenting as extension of \\>2cm into the IVC from the CIV\n* Symptomatic PE with right heart strain where the physician judges that a DVT intervention is inappropriate at this time.\n* Inability to be a candidate for intervention due to medical or technical reasons based on physician judgement\n* Severe allergy, hypersensitivity to, or thrombocytopenia from heparin\n* Severe allergy to iodinated contrast agents that cannot be mitigated\n* Hemoglobin \\\u003C 8.0 g\u002FdL, INR \\> 1.7 before warfarin was started, or platelets \\\u003C 50,000\u002Fµl which cannot be corrected prior to enrollment\n* Severe renal impairment (estimated GFR \\\u003C 30 ml\u002Fmin) in patients who are not yet on dialysis\n* Inability to provide therapeutic anticoagulation per Investigator discretion\n* Uncontrolled severe hypertension on repeated readings (systolic \\> 180mmHg or diastolic \\> 105mmHg)\n* Recently (\\\u003C 30 days) had DVT interventional procedure\n* Subject is participating in another study that may interfere with this study\n* Life expectancy \\\u003C 6 months or chronic non-ambulatory status\n* Known hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period\n* Subject has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject (e.g., contraindication to use of ClotTriever per local approved labeling, compromise the well-being or that could prevent, limit, or confound the protocol-specified assessments)\n* Subject has previously completed or withdrawn from this study\n* Patient unwilling or unable to conduct the follow up visits per protocol","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is a prospective, multicenter, randomized controlled trial of an interventional strategy using the ClotTriever System to achieve and maintain vessel patency (ClotTriever Intervention Arm) versus conservative medical management using anticoagulation therapy alone (Conservative Medical Management Arm) in the treatment of subjects with symptomatic unilateral iliofemoral DVT. The study will collect data on demographics, comorbidities, details from the DVT diagnosis and treatment, and clinical outcomes through the 6-month follow up visit.",[27,28,29],"Venous Thromboembolism","Deep Venous Thrombosis","Post-Thrombotic Syndrome",[27,28,29,31,32],"Anticoagulation","Percutaneous Mechanical Thrombectomy","RECRUITING","2026-08-14",{"date":36,"type":37},"2026-08-18","ACTUAL",{"date":39,"type":37},"2023-01-06",{"date":41,"type":21},"2028-07-31",{"name":43,"class":44},"Inari Medical","INDUSTRY",64,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100651699","outcomes-of-iliac-vein-stenting-with-dedicated-venous-stents-in-treatment-of-chronic-post-thrombotic-venous-ulcers-100651699","NCT07762222","Outcomes of Iliac Vein Stenting With Dedicated Venous Stents in Treatment of Chronic Post-thrombotic Venous Ulcers","Inclusion Criteria:\n\n* Chronic non-healing venous ulcer associated with iliofemoral post-thrombotic syndrome.\n* CEAP clinical classification C6.\n* Iliofemoral post-thrombotic venous obstruction confirmed by appropriate venous imaging.\n* Age 18 years or older.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Nonthrombotic iliac vein lesion (NIVL).\n* Post-phlebitic femoropopliteal venous lesions with a patent iliac vein.\n* CEAP clinical classification other than C6.\n* Previous venous intervention.\n* Active pathological ulcer unrelated to post-thrombotic venous disease.\n* Life expectancy less than 2 years.\n* Pregnancy.\n* Known allergy to contrast media.\n* Contraindication to anesthesia.\n* Refusal to participate or inability to provide informed consent.","70 Years",{"count":54,"type":21},20,[24],"Outcomes of iliac vein stenting with dedicated venous stents in treatment of chronic post-thrombotic venous ulcers Deep vein thrombosis (DVT) affects 1 to 3 individuals per 1000 annually. Among these patients, 20% to 50% may develop post-thrombotic syndrome (PTS), with the likelihood varying based on the extent and location of the thrombus. Notably, despite receiving anticoagulation therapy, 5% to 10% of patients may progress to severe PTS, potentially leading to the development of venous ulcers (Afsha Aurshina, 2018). Chronic venous obstruction (CVO) refers to the impediment of venous flow, typically resulting from either partial or complete blockage of the venous system. This obstruction leads to diminished venous flow and elevated pressure within the affected veins. CVO serves as a broad descriptor for various conditions, including post-thrombotic syndrome (PTS) and nonthrombotic iliac vein lesions (NIVLs). PTS commonly arises as a complication of deep vein thrombosis (DVT), with estimates indicating that up to 50% of patients diagnosed with iliofemoral DVT will develop PTS within two years following their initial diagnosis. (Mohammad E. Barbati, 2024)\n\nThe study aims to know the outcomes of iliac vein stenting with dedicated venous stenting in the treatment of post-thrombotic syndrome venous ulcer.\n\nType of Study: Prospective single arm cohort study\n\n* Study Setting: Ain Shams University hospitals\n* Study Period: 2 years with 6 months follow up\n* Sample Size: 20 patients.\n* Study Population Patients presenting to the outpatient clinic at Ain Shams University Hospitals with venous ulcers.\n* Study Tools\n\n  * 20 patients will be selected.\n  * Written informed consent.\n  * Full history taking, personal history , risk factors of DVT, presence of any medical illness , assessment of QOL based on CVIQ 20 - questionnaire, list of symptoms, sensations or types of discomfort that you may or may not be experiencing and which may make everyday life hard to bear to a greater or lesser extent.\n  * Clinical evaluation: based on revised Venous Clinical Severity Score rVCSS , Villalta score and CEAP classification . rVCSS includes 10 items, such as pain, varicose veins, oedema, skin pigmentation, inflammation, skin induration, number of active ulcers, ulcer size, duration of ulcer, and application of pressure therapy. Each item is scored from 0 to 3 according to the severity, and the total score is 30. A higher score indicates higher severity. And using villlata score It can be used to both diagnose and categories the severity of the condition. The Villalta score involves both the patient who grades the presence and severity (0-3 points) of five symptoms ( pain , cramps, heaviness, parasthesia and pruritus ) and and the physician who grades six clinical signs(Pre-tibial oedema, Hyper-pigmentation, Redness, Venous Ectasia, ain on calf compression, ulcers) (0-3 points) after examination of the lower limb. Also the clinical severity of the venous disease will be graded according to the clinical, etiological, anatomical, and pathophysiological (CEAP) scoring system, and assessment of venous ulcer assessment (by onset, course, duration, site, size, shape",[58,59,60,61],"Vascular","DVT - Deep Vein Thrombosis","Post Thrombotic Syndrome","Venous Ulcer of Leg",[63,64,65],"iliofemoral postthrombotic syndrome","venous ulcer","dedicated iliac venous stenting","2026-08-08",{"date":68,"type":37},"2026-08-13",{"date":70,"type":37},"2025-03-02",{"date":72,"type":21},"2027-01-01",{"name":74,"class":75},"Ain Shams University","OTHER",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":4},"100629331","incidence-and-characteristic-of-crt-persistent-after-catheter-extraction-in-icu-patients-100629331","NCT07473284","Incidence and Characteristic of CRT Persistent After Catheter Extraction in ICU Patients","Incidence and Characteristics of Venous Catheter-related Thrombosis Persisting After Catheter Removal in Intensive Care Unit Patients.","CRT-PERSIST","Inclusion Criteria:\n\n* age over 18 years\n* ICU hospitalization\n* signed informed consent\n* an indwelling central venous catheter planned for extraction\n\nExclusion Criteria:\n\n* age under 18 years\n* local pathology precluding ultrasound examination\n* disagreement with participation in the study",{"count":20,"type":21},"OBSERVATIONAL","The goal of this observational study is to describe characteristics of catheter related thrombosis (CRT) that persists after catheter extraction in condition of intensive care unit. The main questions it aims to answer are:\n\n1. What is the incidence of CRT that persists after catheter extraction in patients hospitalized in the intensive care unit?\n2. What are the risk factors for this phenomenon?\n3. What is the fate of such a thrombus, including recanalization or the development of complications such as pulmonary embolism or post-thrombotic syndrome?",[89,60,90],"Catheter Thrombosis","Pulmonary Embolism (Diagnosis)",[92,93,94],"CRT","Persistent thrombosis","Thrombotic complication","NOT_YET_RECRUITING","2026-03-10",{"date":98,"type":37},"2026-03-16",{"date":100,"type":21},"2026-04-01",{"date":102,"type":21},"2028-01-01",{"name":104,"class":75},"Masarykova Nemocnice v Usti nad Labem, Krajska Zdravotni a.s.",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":117,"conditions":118,"keywords":123,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":4},"100626199","phase-3-design-and-rationale-of-the-colt-study-100626199","NCT07432529","Design and Rationale of the COLT Study","Design and Rationale of the COLT Study: a Multicentre, Randomised, Double-blind, Placebo-controlled Trial of COLchicine as Adjunctive Therapy to Standard Anticoagulation in Acute Proximal Deep Vein Thrombosis of the Lower Limbs","COLT","Inclusion Criteria:\n\n1. Age ≥18 years at the time of screening.\n2. Objectively confirmed first, symptomatic acute proximal lower-limb deep vein thrombosis (DVT), involving the popliteal vein or more proximal veins, diagnosed within the previous 48 hours.\n3. Planned initiation of standard anticoagulation therapy, including:\n\n   * Low-molecular-weight heparin (LMWH) bridging to vitamin K antagonists (VKA) or direct oral anticoagulants (DOACs),\n   * DOAC monotherapy according to local guidelines,\n   * Fondaparinux or other guideline-recommended regimens. Note: Standard anticoagulation regimens include dose reduction of apixaban or rivaroxaban at the sixth month, as per local practice.\n4. Ability and willingness to provide written informed consent and comply with all study procedures.\n\nExclusion Criteria:\n\nParticipants meeting any of the following criteria will be excluded:\n\n1. History of prior DVT in the same limb.\n2. Known contraindications to anticoagulation or anticipated inability to comply with study procedures.\n3. Current use of colchicine or clinical indication requiring colchicine therapy.\n4. Known hypersensitivity or allergy to colchicine.\n5. Severe hepatic impairment, defined as ALT or AST \\>3× upper limit of normal, or severe renal impairment (creatinine clearance \\\u003C30 mL\u002Fmin).\n6. Active malignancy with an estimated life expectancy \\\u003C12 months.\n7. History of active or chronic gastrointestinal disease that may interfere with colchicine tolerance, including:\n\n   1. Inflammatory bowel disease (Crohn's disease or ulcerative colitis),\n   2. Collagenous colitis,\n   3. Irritable bowel syndrome,\n   4. Chronic or recurrent diarrhea.\n8. Recent (\\\u003C30 days) or ongoing use of systemic immunosuppressive therapy, including but not limited to corticosteroids, cyclosporine, or tumor necrosis factor-alpha inhibitors.\n9. Pregnancy or breastfeeding, or unwillingness to use effective contraception during the study period.\n10. Concomitant use of strong CYP3A4 inhibitors or P-glycoprotein inhibitors contraindicated with colchicine.\n11. Major bleeding event within the past 30 days or assessed as high bleeding risk by the investigator.\n12. Inability or unwillingness to provide informed consent or to comply with study procedures.",{"count":114,"type":21},940,[116],"PHASE3","Deep vein thrombosis (DVT) is a condition in which a blood clot forms in the deep veins of the leg and can lead to long-term problems such as leg pain, swelling, and reduced quality of life. Standard treatment with blood-thinning medication lowers the risk of complications, but some patients still develop long-term damage to the veins. Inflammation is thought to play an important role in these complications.\n\nThis study will evaluate whether adding colchicine, an anti-inflammatory medication already used for other conditions, to standard anticoagulant therapy can improve outcomes in patients with acute DVT. Participants will be randomly assigned to receive either colchicine or a placebo, in addition to usual blood-thinning treatment, and will be followed for one year.\n\nThe main goal of the study is to determine whether colchicine reduces the risk of developing long-term vein problems after DVT. The study will also assess the risk of new blood clots, vein recovery, quality of life, and the safety of colchicine treatment.",[119,120,121,122],"Venous Thrombosis Deep (Limbs)","Post-thrombotic Syndrome","Venous Thromboembolism (VTE)","Venous Insufficiency",[124,125,126,127,128,129,130],"Deep vein thrombosis","Venous thromboembolism","Post-thrombotic syndrome","Colchicine","Anticoagulation therapy","Randomized controlled trial","Inflammation","2026-02-21",{"date":133,"type":37},"2026-02-25",{"date":135,"type":21},"2026-06-01",{"date":137,"type":21},"2027-06-01",{"name":139,"class":140},"Azienda Sanitaria Locale ASL 6, Livorno","OTHER_GOV",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":22,"phases":150,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":168},"100387045","phase-3-statins-for-venous-event-reduction-in-patients-with-venous-thromboembolism-100387045","NCT04319627","Statins for Venous Event Reduction in Patients With Venous Thromboembolism","SAVER","Inclusion Criteria:\n\n1\\. Symptomatic objectively confirmed proximal leg DVT (above the trifurcation of the popliteal vein) and\u002For PE (segmental or greater) diagnosed in the last 30 days.\n\nExclusion criteria\n\n1. Unable or unwilling to provide written informed consent;\n2. \\\u003C 18 years of age;\n3. Women of childbearing potential unwilling to use appropriate contraception;\n4. Currently prescribed a statin;\n5. A known medical history or current diagnosis of any of the following for which statins are indicated in secondary prevention:\n\n   1. Diabetes;\n   2. Abdominal aortic aneurysm;\n   3. Peripheral arterial disease;\n   4. Stroke;\n   5. Transient ischemic attack (TIA);\n   6. Myocardial infarction (MI);\n   7. Acute coronary syndromes;\n   8. Stable\u002Funstable angina;\n   9. Coronary or other arterial revascularization;\n6. Known diagnosis of hypercholesterolemia or dyslipidemia;\n7. Contraindication to rosuvastatin;\n\n   1. Known hypersensitivity or intolerance to statins;\n   2. History of muscle disorders or statin-related muscle pain;\n   3. Known liver disease (active liver disease, e.g. Hepatitis A, B, C, non-alcoholic fatty liver);\n   4. Chronic kidney disease (creatinine clearance \\\u003C 30ml\u002Fmin);\n   5. Currently pregnant or breast feeding;\n   6. Taking cyclosporine;\n   7. Taking atazanavir\u002Fritonavir;\n   8. Taking darolutamide;\n   9. Taking regorafenib;\n8. Unstable medical or psychological condition that would interfere with trial participation.",{"count":149,"type":21},2700,[116],"The standard or usual treatment for patients diagnosed with deep vein thrombosis or pulmonary embolism is treatment with blood thinners (called anticoagulants).\n\nWhile treatment of blood clots with blood thinners is effective, some research has shown that adding a statin (medication used to lower cholesterol) may give extra protection. It is thought that statins can improve how cells along the walls of the vein control inflammation, which can prevent new blood clots from forming.\n\nThe medication in this study, rosuvastatin, is approved in Canada for use as a cholesterol-lowering medication. The use of rosuvastatin in this study is considered investigational. This means that Health Canada has not approved the use of rosuvastatin as a treatment for blood clots. However, it has been approved for use in this research study.\n\nThe purpose of this study is to examine if adding a statin (rosuvastatin) to the usual blood thinner treatment will decrease the risk of another blood clot forming. The investigators also hope to discover if taking a statin reduces damage to your veins. To do this, some of the participants in this study will get rosuvastatin and others will receive a placebo (a substance that looks like the study rosuvastatin but does not have any active or medicinal ingredients). The placebo in this study is not intended to have any effect on your blood clot. A placebo is used to make the results of the study more reliable.",[27,153,60],"Blood Clot",[155,156,157,158],"Rosuvastatin","Statin","PTS","VTE","2026-01-13",{"date":161,"type":37},"2026-01-15",{"date":163,"type":37},"2021-02-10",{"date":165,"type":21},"2028-04",{"name":167,"class":75},"Ottawa Hospital Research Institute",31,{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":180,"briefSummary":181,"conditions":182,"keywords":186,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":200},"100587231","phase-3-immunosuppressive-therapy-alone-versus-plus-oral-anticoagulation-in-the-treatment-of-vt-associated-with-behcets-disease-100587231","NCT06925698","Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease","Immunosuppressive Therapy Alone Versus Immunosuppressive Therapy Plus Oral Anticoagulation in the Treatment of Lower Extremity Venous Thrombosis Associated With Behcet's Disease","BETTER","Inclusion Criteria:\n\n* Participants must meet the following criteria to be eligible for the study:\n\nAge between 18-50 years old. Diagnosed with Behçet's Disease according to the International Study Group (ISG) criteria.\n\nNo prior vascular involvement or no previous immunosuppressive therapy for vascular involvement.\n\nConfirmed venous thrombosis in the lower extremity within the last 14 days before randomization.\n\nVenous thrombosis diagnosis confirmed by:\n\nNon-compressible venous segment in ultrasound, OR A significant (\\>4 mm) increase in thrombus diameter in an already abnormal segment, OR New intraluminal filling defect on venography, CT, or MR angiography.\n\nFemale participants must:\n\nNot be pregnant or breastfeeding. Use effective contraception if of childbearing potential. Be postmenopausal (no menses for at least 1 year) or have undergone surgical sterilization.\n\nAbility to provide written informed consent and comply with study requirements.\n\nExclusion Criteria:\n\n* Participants will be excluded if they meet any of the following criteria:\n\nPresence of any aneurysm. Chronic multisystemic disease other than Behçet's Disease. History of intolerance to Rivaroxaban. Use of immunosuppressive drugs (azathioprine, mycophenolate mofetil, cyclosporine, cyclophosphamide, TNF inhibitors, or interferon-gamma) within the last 6 months.\n\nProlonged corticosteroid use (\\>3 months) for Behçet's Disease mucocutaneous symptoms.\n\nPrior anticoagulant therapy:\n\nLow molecular weight heparin, fondaparinux, or unfractionated heparin for \\>48 hours before randomization.\n\nMore than one dose of vitamin K antagonists before randomization. Thrombectomy, vena cava filter placement, or fibrinolytic therapy for the current thrombotic episode.\n\nPlanned administration of a live vaccine within 30 days after randomization. Clinically significant acute or uncontrolled chronic diseases (e.g., cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, malignancy, or infectious diseases) that may interfere with study results.\n\nPlanned surgical procedure or significant medical condition deemed unsuitable for the study by the investigator.\n\nHistory of malignancy within the last 5 years (except adequately treated basal or squamous cell carcinoma or carcinoma in situ of the cervix).\n\nRenal impairment (Creatinine clearance \\\u003C30 ml\u002Fmin). Severe liver disease (e.g., acute hepatitis, active chronic hepatitis, cirrhosis, or ALT \\>3 times the upper limit).\n\nActive bleeding or high bleeding risk contraindicating anticoagulant therapy. Uncontrolled hypertension (SBP \\>180 mmHg or DBP \\>110 mmHg). Severe anemia (Hemoglobin \\\u003C10 mg\u002FdL). Women who are pregnant, breastfeeding, or of childbearing potential without contraception.\n\nUse of strong CYP3A4 inhibitors or inducers (e.g., protease inhibitors, systemic ketoconazole, rifampin, carbamazepine, phenytoin).\n\nParticipation in another experimental drug study within the last 30 days. Life expectancy of less than 3 months. History of serious infections within the last 60 days (e.g., bacterial endocarditis, tuberculosis, opportunistic infections).\n\nActive substance or alcohol abuse or history of substance dependence within the last year.\n\nPositive screening for Hepatitis B surface antigen, Hepatitis C antibody, or known HIV-1 infection.\n\nKnown coagulation disorders or laboratory abnormalities (e.g., DMID toxicity scale Grade 3 or higher).\n\nHistory of suicidal behavior in the last 6 months or suicidal ideation (C-SSRS type 4 or 5) in the last 2 months.","50 Years",{"count":179,"type":21},110,[116],"This study is a Phase III, multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial investigating the treatment of lower extremity venous thrombosis associated with Behçet's Disease. The study compares the effectiveness and safety of immunosuppressive therapy alone versus immunosuppressive therapy combined with oral anticoagulation (Rivaroxaban).",[183,184,185,60],"Behcet Disease","Behcet Disease and Vascular Involvement","Deep Venous Thromboses",[187,188,189,190],"Behcet's disease","Deep venous thrombosis","Anticoagulant therapy","Rivaroxaban","2025-04-07",{"date":193,"type":37},"2025-04-13",{"date":195,"type":21},"2025-04-30",{"date":197,"type":21},"2028-04-01",{"name":199,"class":75},"Marmara University",2]